Mesoblast receives clearance to begin first European trial of allogeneic or 'off-the-shelf' stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited has announced that it had received clearance from the European Medicines Agency to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor(TM) is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction)